lncRNA Expression-Based Risk Scoring System Can Predict Survival of Tumor-Positive Patients with Hepatocellular Carcinoma

Document Type : Research Articles


Department of Medical Oncology, Guangxi Medical University Cancer Hospital, 71 Hedi Road, Nanning 530021, People’s Republic of China.


Background: Long non-coding RNAs (lncRNAs) play critical roles in the progression of hepatocellular carcinoma (HCC). The aim of this study was to explore whether lncRNA expression profiles can predict prognosis of HCC patients with tumors. Methods: Expression of lncRNAs in HCC patients based on data in The Cancer Genome Atlas (TCGA) was examined by uni- and multivariate cox analysis to identify associations between clinical features and overall survival (OS) or recurrence-free survival (RFS). Based on our finding that both were independently associated with tumor status, we examined lncRNAs differentially expressed between patients with or without tumors. An lncRNA-based risk scoring system was developed to predict OS and RFS in tumor-positive patients, and it was assessed using uni- and multivariate cox analyses. Potential functions of the prognostic lncRNAs were explored. Results: A risk scoring system to predict OS for HCC patients with tumors was developed based on the expression of six lncRNAs (AC090921.1, AC012640.1, AL158839.1, AL356056.1, AL359853.1 and C10orf91), and a corresponding scoring system to predict RFS was developed from nine lncRNAs (AL356056.1, AL158839.1, MIR7-3HG, AL445493.2, AP000808.1, AP003354.2, PLCE1-AS1, TH2LCRR and LINC01447). Both risk scoring systems gave areas under receiver operating characteristic curves >0.7. Uni- and multivariate cox analyses showed that both risk scoring systems independently predicted survival even after adjusting for clinical factors. The lncRNAs related to OS may be involved in complement and coagulation cascades, while those related to RFS may be involved in the cell cycle. Conclusion: Risk scoring system based on these lncRNAs may be useful for predicting prognosis of tumor-positive HCC patients.


Main Subjects